bullish

Novotech Health IPO: Structural Tailwinds in the APAC Biotech CRO Market Offers LT Growth

294 Views07 Sep 2021 00:13
Novotech is well positioned to benefit from the tailwinds in the APAC clinical CRO market where it generates a majority of its revenue from China, South Korea and ANZ that drive most of the growth.
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
  • Unlock all research summaries
  • Follow top, independent analysts
  • Receive personalised alerts and emails
  • Access Briefings, Analytics, and Events

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 7-minute read)
Discussions
(Paid Plans Only)
chart-bar
x